When and how can Healthcare Database Analyses replace RCTs in marketed medications?

Size: px
Start display at page:

Download "When and how can Healthcare Database Analyses replace RCTs in marketed medications?"

Transcription

1 Third Plenary WHEN DO WE REALLY NEED RANDOMIZED CONTROLLED TRIALS? Sebastian Schneeweiss, MD, ScD Brigham & Women s Hospital and Harvard Medical School Boston, MA, USA When and how can Healthcare Database Analyses replace s in marketed medications? Sebastian Schneeweiss Division of Pharmacoepidemiology and Pharmacoeconomics, Dept. of Medicine, Brigham & Women s Hospital/ Harvard Medical School Disclosures: PI, Harvard Brigham & Women s Hospital Drug Safety Research Center (FDA) Co Chair, Methods Core of the FDA Sentinel System Consulting in past year: WHISCON LLC, Aetion Inc. (incl. equity) PI of research contracts to the Brigham & Women s Hosp.: Bayer, Genentech, Boehringer Ingelheim Grants/contracts from NIH, AHRQ, PCORI, FDA, IMI Advising FDA, EMA, PCORI, Health Canada 1

2 Real World Data in Pharmacoepidemiology Non experimental data 10% Research data Data collected PRIMARILY for research 90% Transactional data Data used SECONDARILY for research Example For purpose Data specifically for study purpose Framingham Study Cardiovas Health Study Slone Birth Defects Study Some registries Other purpose Data intended for other studies Nurses Health Study 1 Some registries Other purpose Clinical documentation EHR based studies NDI linkage Lab test databases Some registries Administrative Claims data studies Geocoding/census Database Studies CV Safety Example: BART 2

3 CV Safety Example: BART CV Safety Example: ENTRACTE Effectiveness Example: 3

4 Effectiveness Example: Effectiveness Example: HR = 0.66 ( ) HR = 0.77 ( ) 4

5 Effectiveness Example: Why did these database studies come to the HR = 0.66 ( ) HR = 0.77 ( ) same causal conclusion? Effectiveness Example: HR = 0.66 ( ) HR = 0.77 ( ) How confident are we that the study we plan will get it right? 5

6 Less helpful summarization of vs. non experim l: Hemkens et al. BMJ 2016 A corrected re analysis of Hemkens et al. BMJ 2016 Franklin JM, Rothman K, et al.: A Bias in the Evaluation of Bias Comparing Randomized Trials with Non experimental Studies. Epidemiology Methods 2017 Re analysis of treatment effects on mortality in RCD studies and s. For each clinical question, we present the relative odds ratio reported in trial evidence versus the corresponding RCD study. Effect estimates are presented when inverting treatment groups and ORs whenever the OR>1. 6

7 Following 3 guide posts 1. Active Comparator, same treatment modality 2. New Users 3. High-dimensional proxy adjustment result in 1. Clinical relevance 2. Meaningful causal statement 3. High validity 7

8 How to Investigatorcontrolled Datadependent 4. Outcome observable with specificity 5. Achieve covariate balance 6. Avoid known design flaws: a) Avoid immortal time bias b) Avoid adjusting for causal intermediates c) Avoid reverse causation d) Deal with time-varying hazards 7. Do robustness checks When to work with non experimental RWD studies for regulatory and payer decision making? Active comparator Same treatment modality comparator Outcome measureable How to Consider points 4 7 RWE software platforms improve quality, transparency Conduct feasibility analyses; Proceed if balance achieved in measured and UNMEASURED 8

9 When to work with non experimental RWD studies for regulatory and payer decision making? Active comparator Same treatment modality comparator Outcome measureable How to Consider points 4 7 RWE software platforms improve quality, transparency Conduct feasibility analyses; Proceed if balance achieved in measured and UNMEASURED There are >15 CV safety trials currently committed to FDA. If few of those could be replaced with RWE studies this would be a game changer. Effectiveness Example: HR = 0.66 ( ) HR = 0.77 ( ) What do we need to show to develop the confidence that the next RWE study will get it right? 9

10 Baseline Randomization Controlled measurement Seeming simplicity of design No randomization Non standardized observations Seeming complexity of design A priori confidence in causal conclusions What is our confidence level? What do we need to do to gain a priori confidence in causal conclusions? 10

Pharmacovigilance & Signal Detection

Pharmacovigilance & Signal Detection Pharmacovigilance & Signal Detection 30 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Pre-conference educational session Thursday, October 23, 2014; 2:00-6:00pm Semi-automated,

More information

Framework for FDA s Real-World Evidence Program

Framework for FDA s Real-World Evidence Program Framework for FDA s Real-World Evidence Program Jacqueline Corrigan-Curay, J.D., M.D. Director, Office of Medical Policy Center for Drug Evaluation and Research Food and Drug Administration March 15, 2019

More information

Large electronic healthcare databases for medical product safety surveillance The U.S. FDA Mini-Sentinel project

Large electronic healthcare databases for medical product safety surveillance The U.S. FDA Mini-Sentinel project Large electronic healthcare databases for medical product safety surveillance The U.S. FDA Mini-Sentinel project Darren Toh, ScD Department of Population Medicine Harvard Medical School and Harvard Pilgrim

More information

Using local RWD to drive global therapeutic advancements.

Using local RWD to drive global therapeutic advancements. Using local RWD to drive global therapeutic advancements. Helsinki, 30 th Nov 2016 Mike Spencer, Head of Real World Evidence, EMEA, Janssen The following represent my own views and not necessarily those

More information

The Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices

The Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices The Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices Owen Faris, Ph.D. Director, Clinical Trials Program Office of Device Evaluation Center for Devices and Radiological

More information

Regulatory challenges and opportunities for the use of Real World Evidence for drug registration and labelling

Regulatory challenges and opportunities for the use of Real World Evidence for drug registration and labelling Presentation title Date 1 Regulatory challenges and opportunities for the use of Real World Evidence for drug registration and labelling Marianne Bork Samuelsen, Msc Pharm Regulatory Affairs Novo Nordisk

More information

CRNs as Foundational Blocks of the National Evaluation System for Medical Devices: A Call to Action

CRNs as Foundational Blocks of the National Evaluation System for Medical Devices: A Call to Action CRNs as Foundational Blocks of the National Evaluation System for Medical Devices: A Call to Action Danica Marinac Dabic, MD, PhD Director, Division of Epidemiology Summary FDA Strategic Priorities: 2016

More information

Precision Medicine: Harnessing Biomedical Data to Improve the Prediction, Prevention, Diagnosis and Treatment of Disease

Precision Medicine: Harnessing Biomedical Data to Improve the Prediction, Prevention, Diagnosis and Treatment of Disease Precision Medicine: Harnessing Biomedical Data to Improve the Prediction, Prevention, Diagnosis and Treatment of Disease Session #61, February 20, 2017 Jason Levine, MD, Assoc. Director of Clinical Informatics,

More information

European contribution to the RWD/RWE debate. Alasdair Breckenridge July 2018

European contribution to the RWD/RWE debate. Alasdair Breckenridge July 2018 European contribution to the RWD/RWE debate Alasdair Breckenridge July 2018 Sources UK Academy of Medical Sciences(AMS) workshops European Medicines Agency (EMA) Innovative Medicines Initiative (IMI) projects

More information

Current State of Endpoint Adjudication in Device Trials Academic View

Current State of Endpoint Adjudication in Device Trials Academic View HARVARD MEDICAL SCHOOL Current State of Endpoint Adjudication in Device Trials Academic View CSRC/MDEpiNet Device Adjudication March 11, 2016 Donald E. Cutlip, MD Harvard Clinical Research Institute Smith

More information

Data Quality in the Real World: Ensuring Integrity across the Medical Device Lifecycle

Data Quality in the Real World: Ensuring Integrity across the Medical Device Lifecycle Data Quality in the Real World: Ensuring Integrity across the Medical Device Lifecycle Moderated by Karen Conway, GHX Panelists: Steven Luxenberg, MD, U.S. FDA CDRH Dennis Black, BD Robert Lynch, Franciscan

More information

1. POLICY STATEMENT: 2. BACKGROUND:

1. POLICY STATEMENT: 2. BACKGROUND: POLICY #: RCO-201 Page: 1 of 5 1. POLICY STATEMENT: All Food and Drug Administration (FDA) regulated research conducted under an Investigational New Drug Application (IND) and managed within DF/HCC requires

More information

Everything You Wanted to Know About ClinicalTrials.gov*

Everything You Wanted to Know About ClinicalTrials.gov* Everything You Wanted to Know About * Deborah A. Zarin, MD Director, National Library of Medicine (*But Were Afraid to Ask) DISCLAIMER Views are mine and do not necessarily represent views of NIH or HHS

More information

THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION

THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices

More information

Overview of FDA s Sentinel Initiative

Overview of FDA s Sentinel Initiative Overview of FDA s Sentinel Initiative Judy Racoosin, Sentinel Initiative Scientific Lead, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration September

More information

Potential Steps in Active Surveillance

Potential Steps in Active Surveillance Background The Sentinel System will augment FDA s postmarket safety assessment capabilities by enhancing its capacity to conduct active surveillance at the population level. Conducting active surveillance

More information

Emerging study designs - The need of real world evidence to validate safety and efficacy results from clinical trials

Emerging study designs - The need of real world evidence to validate safety and efficacy results from clinical trials 14MAR2018 1 Emerging study designs - The need of real world evidence to validate safety and efficacy results from clinical trials Symposium Drug Research Academy March 14 2018 Atheline Major-Pedersen MD,

More information

Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality

Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality Hua Xu, PhD School of Biomedical Informatics, UTHealth JAMIA Journal

More information

2018 Data Science Summit: The Economics Of Artificial Intelligence In Healthcare

2018 Data Science Summit: The Economics Of Artificial Intelligence In Healthcare May 30, 2018 2018 Data Science Summit: The Economics Of Artificial Intelligence In Healthcare Making AI Work In Clinical Practice Bibb Allen, MD FACR Chief Medical Officer ACR Data Science Institute OVERVIEW

More information

Real World Evidence Generation in the 21 st Century: National Evaluation System for health Technology (NEST)

Real World Evidence Generation in the 21 st Century: National Evaluation System for health Technology (NEST) Real World Evidence Generation in the 21 st Century: National Evaluation System for health Technology (NEST) Bill Murray, President & CEO IDEAL Conference Presentation May 5, 2017 1 www.mdic.org Vision

More information

Public - Private Partnerships in Europe and ENCePP Initiative

Public - Private Partnerships in Europe and ENCePP Initiative Public - Private Partnerships in Europe and ENCePP Initiative Henry Fitt Section Head, Co-ordination & Networking, Pharmacovigilance and Risk Management European Medicines Agency 22nd Annual EuroMeeting

More information

RWE Best Practices: Lessons from the US

RWE Best Practices: Lessons from the US RWE Best Practices: Lessons from the US Canadian Assoc. for Population Therapeutics Nancy A. Dreyer Chief Scientific Officer December 13, 2018 Copyright 2017 IQVIA. All rights reserved. MEET THE SPEAKER

More information

RWE Best Practices: Lessons from the US

RWE Best Practices: Lessons from the US RWE Best Practices: Lessons from the US Canadian Assoc. for Population Therapeutics Nancy A. Dreyer Chief Scientific Officer December 13, 2018 Copyright 2017 IQVIA. All rights reserved. MEET THE SPEAKER

More information

Leveraging Prognostic Baseline Variables in RCT. Precision in Randomized Trials

Leveraging Prognostic Baseline Variables in RCT. Precision in Randomized Trials Leveraging Prognostic Baseline Variables to Gain Precision in Randomized Trials Michael Rosenblum Associate Professor of Biostatistics Johns Hopkins Bloomberg School of Public Health (JHBSPH) Joint work

More information

Real-World Data & Life Science Analytics Congress

Real-World Data & Life Science Analytics Congress 25 th -26 th October 2018, Boston Real-World Data & Life Science Analytics Congress Event Overview As healthcare organizations move forward into the bold new world of value-based payments, they need to

More information

Don Rucker, M.D. National Coordinator Office of the National Coordinator for Health Information Technology 330 C Street, SW Washington, DC 20201

Don Rucker, M.D. National Coordinator Office of the National Coordinator for Health Information Technology 330 C Street, SW Washington, DC 20201 October 17, 2018 Don Rucker, M.D. National Coordinator Office of the National Coordinator for Health Information Technology 330 C Street, SW Washington, DC 20201 Re: Request for Information Regarding the

More information

Using Real-World Evidence (RWE) for Regulatory Decision Making and Pracatice. Danica Marinac-Dabic, MD, PhD Director, Division of Epidemiology

Using Real-World Evidence (RWE) for Regulatory Decision Making and Pracatice. Danica Marinac-Dabic, MD, PhD Director, Division of Epidemiology Using Real-World Evidence (RWE) for Regulatory Decision Making and Pracatice Danica Marinac-Dabic, MD, PhD Director, Division of Epidemiology Summary RWE context Selected Examples of Early Successes and

More information

NESTcc Call for Concepts Public Webinar. Rachael L. Fleurence, PhD. NESTcc Executive Director January 4, 2018

NESTcc Call for Concepts Public Webinar. Rachael L. Fleurence, PhD. NESTcc Executive Director January 4, 2018 Dial-In: +1-415-655-0002 Access code: 662 348 083 Join Online: https://mdic.webex.com/mdic/ onstage/g.php?mtid=edc86dc3 ee6a3970422222c725600570b NESTcc Call for Concepts Public Webinar Rachael L. Fleurence,

More information

What We Learned Running Investigator Initiated Trials

What We Learned Running Investigator Initiated Trials What We Learned Running Investigator Initiated Trials James D. Lewis, MD, MSCE Division of Gastroenterology Center for Clinical Epidemiology & Biostatistics University of Pennsylvania Hans Herfarth, MD,

More information

Signal Detection Quantitative Analysis of Safety Data. Dr. Yusuf Tanrikulu Basel, 29th November 2016

Signal Detection Quantitative Analysis of Safety Data. Dr. Yusuf Tanrikulu Basel, 29th November 2016 Signal Detection Quantitative Analysis of Safety Data Dr. Yusuf Tanrikulu Basel, 29th November 2016 Contents Regulatory background Goals of signal detection Data sources Methods Recent developments 2 Regulatory

More information

Missing Data Handling in Non-Inferiority & Equivalence Trials

Missing Data Handling in Non-Inferiority & Equivalence Trials Missing Data Handling in Non-Inferiority & Equivalence Trials A systematic review Brooke A Rabe Graduate Interdisciplinary Program in Statistics The University of Arizona, Tucson, USA PSI s Pharmaceutical

More information

Use of Real World Data in Development Programmes

Use of Real World Data in Development Programmes Use of Real World Data in Development Programmes Dr Alison Cave and Dr Francesca Cerreta Industry Stakeholder Platform on Research and Development Support 25 April 2017 An agency of the European Union

More information

Comparing the use of OMOP and Sentinel CDMs for Drug Safety Implications for European Data

Comparing the use of OMOP and Sentinel CDMs for Drug Safety Implications for European Data Comparing the use of OMOP and Sentinel CDMs for Drug Safety Implications for European Data Andrew Bate Senior Director, Epidemiology Group Lead, Analytics A Common Data Model for Europe? Why? Which? How?

More information

PCWP and HCPWP work programmes for 2013

PCWP and HCPWP work programmes for 2013 PCWP and HCPWP work programmes for 2013 Presented by: Ivana Silva and Nathalie Bere P-MI-PIN Public Information and Stakeholder Networking An agency of the European Union Meetings scheduled for 2013 27

More information

RAPID Phase 1 Deliverables Use Cases, Flow Diagrams

RAPID Phase 1 Deliverables Use Cases, Flow Diagrams RAPID Phase 1 Deliverables Use Cases, Flow Diagrams James E. Tcheng, MD Duke Clinical Research Institute Durham, NC RAPID Think Tank 14 September 2016 1 Use Cases: Background & Rationale Why Use Cases?

More information

Proof of Concept Vs Proof of Value

Proof of Concept Vs Proof of Value Evidence Requirements Supporting Critical Decisions in Pharmacotherapeutics: Proof of Concept Vs Proof of Value RG Peterson MD, PhD, MPH Executive Director Drug Safety and Effectiveness Network Canadian

More information

Incorporating Evidence from Clinical Experience into Regulatory Decision- Making: A Pragmatic Approach to Randomization in the Clinical Setting

Incorporating Evidence from Clinical Experience into Regulatory Decision- Making: A Pragmatic Approach to Randomization in the Clinical Setting Incorporating Evidence from Clinical Experience into Regulatory Decision- Making: A Pragmatic Approach to Randomization in the Clinical Setting Washington Plaza Hotel Washington, DC January 15, 2016 Meeting

More information

EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY

EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY PREAMBLE The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the

More information

Jeffrey Brown, PhD. November 12, 2013 Department of Population Medicine Harvard Pilgrim Health Care Institute/ Harvard Medical School

Jeffrey Brown, PhD. November 12, 2013 Department of Population Medicine Harvard Pilgrim Health Care Institute/ Harvard Medical School info@mini-sentinel.org 1 Biosimilar Collective Intelligence System: Utilizing Data Consortiums to Prove Safety and Effectiveness of Biosimilars Reviewing current landscape of existing data consortiums:

More information

Pharmacoepidemiology. Dr. Mahyar Etminan Scientist Department of Medicine, UBC

Pharmacoepidemiology. Dr. Mahyar Etminan Scientist Department of Medicine, UBC Pharmacoepidemiology Dr. Mahyar Etminan Scientist Department of Medicine, UBC Contacts Email: metminan@shaw.ca Tel: 604-875-2000 (7954) What is pharmacoepidemiology? study of drug efficacy, toxicity and

More information

1201 Maryland Avenue SW, Suite 900, Washington, DC ,

1201 Maryland Avenue SW, Suite 900, Washington, DC , 1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org June 6, 2008 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville, MD

More information

FDA Experience with the Sentinel Common Data Model: Addressing Data Sufficiency

FDA Experience with the Sentinel Common Data Model: Addressing Data Sufficiency FDA Experience with the Sentinel Common Data Model: Addressing Data Sufficiency Michael D. Nguyen, MD Office of Surveillance and Epidemiology Center for Drug Evaluation and Research US Food and Drug Administration

More information

UDI in the US. Ms. Terrie Reed, Senior Advisor for UDI Adoption U.S. Food and Drug Administration. 19 October 2017

UDI in the US. Ms. Terrie Reed, Senior Advisor for UDI Adoption U.S. Food and Drug Administration. 19 October 2017 UDI in the US Ms. Terrie Reed, Senior Advisor for UDI Adoption U.S. Food and Drug Administration 19 October 2017 UDI: Regulatory Update Terrie L. Reed, MS. Ind. Engineering Center for Devices and Radiological

More information

Toward Greater Transparency and Rigor

Toward Greater Transparency and Rigor Toward Greater Transparency and Rigor TRANSPARENCY: ClinicalTrials.gov registration and results reporting The Center for Clinical & Translational Science 205.934.7442 ccts@uab.edu www.uab.edu/ccts @cctsnetwork

More information

BETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular

BETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular BETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular Medicine Cardiovascular Division Brigham and Women s Hospital

More information

October 25, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

October 25, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers

More information

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215

More information

Real World Evidence how patient groups can contribute and how to engage patient groups in clinical research

Real World Evidence how patient groups can contribute and how to engage patient groups in clinical research Real World Evidence how patient groups can contribute and how to engage patient groups in clinical research ERIC LOW INDEPENDENT HEALTHCARE CONSULTANT CHAIRMAN AMYLOIDOSIS RESEARCH CONSORTIUM UK FOUNDER

More information

August 25, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

August 25, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 August 25, 2014 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA Docket No. FDA-2014-D-0758-0001 Draft Guidance for Industry on Distributing

More information

Creation of a pan-european Paediatric Clinical Trials Network. Heidrun Hildebrand (Bayer) & William Treem (Janssen),

Creation of a pan-european Paediatric Clinical Trials Network. Heidrun Hildebrand (Bayer) & William Treem (Janssen), Creation of a pan-european Paediatric Clinical Trials Network Heidrun Hildebrand (Bayer) & William Treem (Janssen), 19.12.2016 IMI webinar Need for public-private collaboration Due to European Regulation,

More information

To begin from the beginning

To begin from the beginning POST-AUTHORISATION STUDIES IN EUROPE: BRIDGING THE GAP BETWEEN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT (HTA) STAKEHOLDER NEEDS BY BETTER DESIGN OF STUDIES Massoud Toussi Epidemiology, Europe Real World

More information

The Right Data for the Right Questions:

The Right Data for the Right Questions: The Right Data for the Right Questions: Evidentiary Needs as a Guide to Data Source Selection David Thompson, PhD Senior Vice President Louise Parmenter, PhD Global Head of Operations Real-World & Late

More information

Regulatory Pathways. Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB

Regulatory Pathways. Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB Regulatory Pathways Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB johnlaschinger@fda.hhs.gov 1 Disclosures and Disclaimer John C. Laschinger, M.D. I am a full

More information

ABOUT THE DUKE-MARGOLIS CENTER FOR HEALTH POLICY

ABOUT THE DUKE-MARGOLIS CENTER FOR HEALTH POLICY ABOUT THE DUKE-MARGOLIS CENTER FOR HEALTH POLICY The Robert J. Margolis, MD, Center for Health Policy at Duke University is directed by Mark McClellan, MD, PhD, and brings together expertise from the Washington,

More information

NDA Requirements: Surveillance, Clinical Trial Data, Breakpoints

NDA Requirements: Surveillance, Clinical Trial Data, Breakpoints NDA Requirements: Surveillance, Clinical Trial Data, Breakpoints Kevin M. Krause Director Microbiology Achaogen, Inc. Presented at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of

More information

Scientific Advisory Groups (SAG)

Scientific Advisory Groups (SAG) Scientific Advisory Groups (SAG) Experience and impact of patient involvement Presented by: Francesco Pignatti Human Medicines Evaluation Division, EMA Training session for patients and consumers involved

More information

A Path from RWD to RWE Stopping Over at Statistical Inference

A Path from RWD to RWE Stopping Over at Statistical Inference A Path from RWD to RWE Stopping Over at Statistical Inference ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop 2018 Scott Snyder, PhD Director, Statistics and Data Science Cook Research

More information

Use of Big Data to Support Regulatory Decision Making

Use of Big Data to Support Regulatory Decision Making Use of Big Data to Support Regulatory Decision Making EMA-EuropaBio Annual Bilateral meeting Dr Alison Cave, Principal Scientific Administrator, Pharmacovigilance and Epidemiology Department An agency

More information

THE CONVERGENCE INITIATIVE TO MAXIMISE THE VALUE FROM EUROPEAN RESEARCH

THE CONVERGENCE INITIATIVE TO MAXIMISE THE VALUE FROM EUROPEAN RESEARCH THE CONVERGENCE INITIATIVE TO MAXIMISE THE VALUE FROM EUROPEAN RESEARCH Georges De Moor EuroRec, Ghent University Electronic Health Records for Clinical Research 192 Growing number of Participating Projects

More information

Study population The study population comprised patients undergoing major hip or knee surgery.

Study population The study population comprised patients undergoing major hip or knee surgery. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients Dranitsaris G, Kahn S R, Stumpo C, Paton T W, Martineau J, Smith R,

More information

Surveillance Part 2. Marcia A. Testa, MPH, PhD Harvard School of Public Health

Surveillance Part 2. Marcia A. Testa, MPH, PhD Harvard School of Public Health Surveillance Part 2 Marcia A. Testa, MPH, PhD Harvard School of Public Health Periodic Population-based Surveys Used for surveillance if surveys are repeated on a regular basis Careful attention to the

More information

UDI COMMUNITY (LUC): RESOURCES AND DELIVERABLES

UDI COMMUNITY (LUC): RESOURCES AND DELIVERABLES LEARNING UDI COMMUNITY Advancing Health Care through Supply Chain Excellence LEARNING UDI COMMUNITY (LUC): RESOURCES AND DELIVERABLES Learning UDI Community WWW.AHRMM.ORG/LUC About AHRMM: The Association

More information

Pragmatic Clinical Trials for Regulatory Decisions

Pragmatic Clinical Trials for Regulatory Decisions Pragmatic Clinical Trials for Regulatory Decisions Jacqueline Corrigan-Curay, MD JD Office of Medical Policy Center for Drug Evaluation and Research FDA May 16, 2018 Pragmatic Clinical Trials Pragmatic

More information

MINI-SENTINEL METHODS PROPENSITY SCORE MATCHING TOOL ENHANCEMENTS REPORT

MINI-SENTINEL METHODS PROPENSITY SCORE MATCHING TOOL ENHANCEMENTS REPORT MINI-SENTINEL METHODS PROPENSITY SCORE MATCHING TOOL ENHANCEMENTS REPORT Prepared by: Joshua J Gagne, PharmD, ScD, 1 Martin Kulldorff, PhD, 4 Shirley V. Wang, PhD, ScM, 1 Ivair Silva, PhD, 6 Bruce Fireman,

More information

Update on Real World Evidence Data Collection

Update on Real World Evidence Data Collection Update on Real World Evidence Data Collection STAMP, 10 March 2016 Presented by Dr Peter Arlett EMA An agency of the European Union What is Real-world evidence? Big data = umbrella term describing large

More information

Comparative Effectiveness Research and Personalized Medicine: Policy, Science and Business. Setting the Stage. October 28, 2009 Washington, DC

Comparative Effectiveness Research and Personalized Medicine: Policy, Science and Business. Setting the Stage. October 28, 2009 Washington, DC Comparative Effectiveness Research and Personalized Medicine: Policy, Science and Business Setting the Stage October 28, 2009 Washington, DC Clifford Goodman, PhD Vice President clifford.goodman@lewin.com

More information

Biomarker Tests for Molecularly Targeted Therapies Key to Unlocking Precision Medicine Report from the National Academy of Medicine

Biomarker Tests for Molecularly Targeted Therapies Key to Unlocking Precision Medicine Report from the National Academy of Medicine Biomarker Tests for Molecularly Targeted Therapies Key to Unlocking Precision Medicine Report from the National Academy of Medicine Robert Nussbaum MD Chief Medical Officer, Invitae Corporation Former

More information

FDA from a Former FDAer: Secrets and insights into regulatory review and drug development

FDA from a Former FDAer: Secrets and insights into regulatory review and drug development FDA from a Former FDAer: Secrets and insights into regulatory review and drug development Andrew E. Mulberg, MD, FAAP Vice-President, Global Regulatory Affairs; Former Division Deputy, DGIEP, U.S. FDA

More information

Interpreting Composite Endpoints in Cardiovascular in Clinical Trials

Interpreting Composite Endpoints in Cardiovascular in Clinical Trials Interpreting Composite Endpoints in Cardiovascular in Clinical Trials Concepts and Controversies Paul W Armstrong MD ACC Rockies Banff Alberta March 13 2017 Disclosure Statement Paul W. Armstrong MD Research

More information

Our comments include three recommendations and the associated rationale:

Our comments include three recommendations and the associated rationale: June 26, 2009 Dr. David Blumenthal Office of the National Coordinator for Health Information Technology Department of Health and Human Services 200 Independence Avenue, SW Washington, DC 20201 Dear Dr.

More information

Natalia Nayanova Director of Clinical Operations and General Manager. Accell Clinical Research 2016

Natalia Nayanova Director of Clinical Operations and General Manager. Accell Clinical Research 2016 Natalia Nayanova Director of Clinical Operations and General Manager Accell Clinical Research 2016 PRESENTATION STRUCTURE Company overview Advantages of the Region FDA & EMA Acceptance Myths vs. Realities

More information

Advance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile?

Advance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile? Advance Topics in Pharmacoepidemiology Risk Management 2012 Mid-Year ISPE Meeting Miami, April 21-23, 2012 Ariel E., Arias MD, PhD - Fac. Pharmacy; Université de Montréal - Biologics & Genetic Therapies

More information

PASS-PAES-HTA studies

PASS-PAES-HTA studies PASS-PAES-HTA studies A view from academia Nicholas Moore University of Bordeaux Disclosure 2 Conflict of interest statement I & my department have worked or are working with, or have received various

More information

Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices

Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices Draft Guidance

More information

The Role of Public-Private Partnerships & Evidence Generation

The Role of Public-Private Partnerships & Evidence Generation The Role of Public-Private Partnerships & Evidence Generation Christina Donatti LLB, BSc, MSc, PsyD IMI Lead, RWE EMEA Strategic Organisation. Janssen Cilag Janssen is proud to feature artwork created

More information

ADAPTIVE PATHWAYS WORKSHOP

ADAPTIVE PATHWAYS WORKSHOP ADAPTIVE PATHWAYS WORKSHOP Stockholm Friday, November 10, 2017 9:00 13:00 Adaptive Pathways Applications for Scientific Insights in Europe PRESENTED BY: An ICON plc Company Agenda Overview 9:00 9:10 9:10

More information

USTGlobal. Big Data Analysis Revolutionizing Healthcare Industry

USTGlobal. Big Data Analysis Revolutionizing Healthcare Industry USTGlobal Big Data Analysis Revolutionizing Healthcare Industry UST Global Inc, October 2017 Table of Contents Introduction The latest trends in healthcare point towards digitalizing the industry, with

More information

RWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.

RWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact. Real Real World World Data Data Across Across the the Product Product Lifecycle: Lifecycle: RWE from pre-clinical to launch RWE from pre-clinical to launch Standard of care Unmet needs Disease burden Budget

More information

SOURCES OF AND METHODS TO REDUCE BIAS IN NON-EXPERIMENTAL STUDIES BRIAN D. BRADBURY, DSC CENTER FOR OBSERVATIONAL RESEARCH

SOURCES OF AND METHODS TO REDUCE BIAS IN NON-EXPERIMENTAL STUDIES BRIAN D. BRADBURY, DSC CENTER FOR OBSERVATIONAL RESEARCH SOURCES OF AND METHODS TO REDUCE BIAS IN NON-EXPERIMENTAL STUDIES BRIAN D. BRADBURY, DSC CENTER FOR OBSERVATIONAL RESEARCH DIFFERENCES IN TREATMENT ASSIGNMENT DETERMINATION BETWEEN EXPERIMENTAL AND NON-EXPERIMENTAL

More information

Models of Industry Trials for Regulatory Purposes (Safety) Frank Cerasoli, PhD OREXIGEN Therapeutics

Models of Industry Trials for Regulatory Purposes (Safety) Frank Cerasoli, PhD OREXIGEN Therapeutics Models of Industry Trials for Regulatory Purposes (Safety) Frank Cerasoli, PhD OREXIGEN Therapeutics Safety Evaluation is Not Completed at Approval Phase 3 programs evaluate efficacy and general safety/tolerability

More information

PROTECT s Impact on Pharmacovigilance Practice: An Industry Perspective

PROTECT s Impact on Pharmacovigilance Practice: An Industry Perspective PROTECT s Impact on Pharmacovigilance Practice: An Industry Perspective Robert Reynolds, ScD Vice President, Epidemiology Pfizer Research & Development ICPE Boston August 25, 2015 Disclosures I am an employee

More information

PRAGMATIC TRIALS AND THE LEARNING HEALTHCARE SYSTEM

PRAGMATIC TRIALS AND THE LEARNING HEALTHCARE SYSTEM PRAGMATIC TRIALS AND THE LEARNING HEALTHCARE SYSTEM INSIGHTS FROM YEAR 1 OF THE NIH COLLABORATORY Sean R. Tunis MD, MSc September 27, 2013 President and CEO Faculty/Presenter Disclosure Speaker Sean Tunis

More information

WINTHER TRIAL: AN SME DRIVEN EUFP7 PROGRAM TO CREATE AN INDUSTRY STANDARD TOOL TO OPTIMIZE THERAPEUTIC DECISION MAKING

WINTHER TRIAL: AN SME DRIVEN EUFP7 PROGRAM TO CREATE AN INDUSTRY STANDARD TOOL TO OPTIMIZE THERAPEUTIC DECISION MAKING WINTHER TRIAL: AN SME DRIVEN EUFP7 PROGRAM TO CREATE AN INDUSTRY STANDARD TOOL TO OPTIMIZE THERAPEUTIC DECISION MAKING Mohammad Afshar, MD, PhD Ariana Pharma WIN Symposium June 2015 - Paris Disclosure

More information

Use of RWE in a regulatory context: issues and examples. Rob Hemmings, MHRA

Use of RWE in a regulatory context: issues and examples. Rob Hemmings, MHRA Use of RWE in a regulatory context: issues and examples Rob Hemmings, MHRA Disclaimer I don t particularly like the terms real world data, real world evidence. To be more precise, I will discuss data generated

More information

Avoiding Conflict of Interest Recognize and Manage COI

Avoiding Conflict of Interest Recognize and Manage COI Avoiding Conflict of Interest Recognize and Manage COI December 2017 Udo Hoffmann, MD, MPH Professor of Radiology, Harvard Medical School Chief, Division of Cardiovascular Imaging, Director Cardiac MR

More information

Large, Simple Trials Policy Needs: Ethics, Trial Processes

Large, Simple Trials Policy Needs: Ethics, Trial Processes Large, Simple Trials Policy Needs: Ethics, Trial Processes Conflicts I have and continue to conduct simple and complex trials funded by industry, NIH and foundations Industry relations can be found at

More information

Use of real world data pre-authorisation what can it answer?

Use of real world data pre-authorisation what can it answer? Use of real world data pre-authorisation what can it answer? Peter Mol -Principal assessor CBG-MEB -SAWP vice-chair (EMA) -Assistant professor, Clinical Pharmacy and Pharmacology, UMC Groningen Disclaimer

More information

PHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008

PHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008 PHARMA CONGRESS October 28, 2008 Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments Beverly H. Lorell, MD Senior Medical & Policy Advisor King & Spalding LLP Assessing

More information

Interfacing Insights. What is Your Data Integrity Model?

Interfacing Insights. What is Your Data Integrity Model? Interfacing Insights What is Your Data Integrity Model? Demand for healthcare interfaces is rising, and there is a rapid pace in which healthcare entities are working to connect various internal applications

More information

Sentinel Journey from Safety Question to Regulatory Action. Rima Izem, PhD

Sentinel Journey from Safety Question to Regulatory Action. Rima Izem, PhD Sentinel Journey from Safety Question to Regulatory Action Rima Izem, PhD rima.izem@fda.hhs.gov Food and Drug Administration Center for Drug Evaluation and Research Division of Biometrics 7 1 Disclaimer

More information

Registry Assessment of Peripheral Interventional Devices (RAPID)

Registry Assessment of Peripheral Interventional Devices (RAPID) Registry Assessment of Peripheral Interventional Devices (RAPID) Pablo Morales, MD FDA Division of Cardiovascular Devices MDEpiNet Annual Meeting October 20, 2017 RAPID moving into full SPEED Pablo Morales,

More information

Indirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee

Indirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee Indirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee 2009 CADTH Symposium April 6, 2009, Ottawa, ON Presentation Outline Background on indirect

More information

10/9/2012. Alicia Joy, IRB. Wednesday October 10, Please be sure to sign in and take copies of each handout.

10/9/2012. Alicia Joy, IRB. Wednesday October 10, Please be sure to sign in and take copies of each handout. Wednesday October 10, 2012 Please be sure to sign in and take copies of each handout. 1 Alicia Joy, IRB 2 FH Office of Research Administration Christina Jackson, BSN, RN, CCRC, CHRC 1 ClinicalTrials.gov

More information

EMA - Early Access. PEARRL Annual Meeting 2017-Regulatory Science Symposium. University College Cork, Ireland

EMA - Early Access. PEARRL Annual Meeting 2017-Regulatory Science Symposium. University College Cork, Ireland EMA - Early Access PEARRL Annual Meeting 2017-Regulatory Science Symposium University College Cork, Ireland Presented by Evangelos Kotzagiorgis Scientific Administrator, Quality of Medicines Office Specialised

More information

BREAKTHROUGH INNOVATION: LESSONS FOR PHARMA R&D

BREAKTHROUGH INNOVATION: LESSONS FOR PHARMA R&D BREAKTHROUGH INNOVATION: LESSONS FOR PHARMA R&D Novasecta: Specialist Pharmaceutical Management Consulting The realities of unrelenting price pressure and patent expiries put a special pressure on pharmaceutical

More information

Regulatory Requirements

Regulatory Requirements Regulatory Requirements CTTI Quality by Design Workshop 28-29 Jan 2013 Rockville, MD Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency An agency of the European Union Disclaimer

More information

Moving UDI from Regulation to Value Within Hospitals and Beyond

Moving UDI from Regulation to Value Within Hospitals and Beyond Moving UDI from Regulation to Value Within Hospitals and Beyond Karen Conway Executive Director, Industry Relations, GHX Terrie Reed, MDEpiNet Coordinating Center Duke Clinical Research Institute Slide

More information

Not My Study Challenges of Clinical Trial Disclosure at an Academic Medical Center

Not My Study Challenges of Clinical Trial Disclosure at an Academic Medical Center Not My Study Challenges of Clinical Trial Disclosure at an Academic Medical Center Office of Research Compliance and Quality Assurance Yolanda P. Davis Sr. Research Compliance Officer Author: Yolanda P.

More information

A Rapid-Learning Health System

A Rapid-Learning Health System A Rapid-Learning Health System Using HIT for Medical Research Lynn Etheredge March 17, 2009 Rapid Breakthrough Science Using IT A new international model for science Large computerized research databases

More information

The European Health Data & Evidence Network

The European Health Data & Evidence Network The European Health Data & Evidence Network What is it? Nigel Hughes EFPIA Coordinator Scientific Director, JCI Patient Data for Research, Janssen 18 th May 2018 1 All too often real world research is

More information